NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $5.00 +0.64 (+14.68%) Closing price 02/18/2025 04:00 PM EasternExtended Trading$5.04 +0.04 (+0.72%) As of 02/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Neuronetics Stock (NASDAQ:STIM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neuronetics alerts:Sign Up Key Stats Today's Range$4.29▼$5.0350-Day Range$1.09▼$5.0052-Week Range$0.52▼$5.07Volume3.65 million shsAverage Volume1.70 million shsMarket Capitalization$151.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingModerate Buy Company OverviewNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More… Neuronetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreSTIM MarketRank™: Neuronetics scored higher than 21% of companies evaluated by MarketBeat, and ranked 877th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingNeuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuronetics has received no research coverage in the past 90 days.Read more about Neuronetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.17% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 11.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.17% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 11.30%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.40 News SentimentNeuronetics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Neuronetics this week, compared to 3 articles on an average week.Search Interest9 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,876.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Stock News HeadlinesNeuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 10,845 SharesFebruary 15, 2025 | insidertrades.comNeuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 14,836 SharesFebruary 13, 2025 | insidertrades.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 19, 2025 | Colonial Metals (Ad)Neuronetics EVP William Andrew Macan sells $46,630 in stockFebruary 14, 2025 | msn.comNeuronetics CFO Stephen Furlong sells $41,536 in stockFebruary 14, 2025 | msn.comNeuronetics CFO Stephen Furlong sells shares worth $48,662February 13, 2025 | msn.comNeuronetics' EVP William Andrew Macan sells $6,461 in stockFebruary 13, 2025 | msn.comNeuronetics CEO Keith Sullivan sells $134,453 in stockFebruary 13, 2025 | msn.comSee More Headlines STIM Stock Analysis - Frequently Asked Questions How have STIM shares performed this year? Neuronetics' stock was trading at $1.61 at the start of the year. Since then, STIM stock has increased by 210.6% and is now trading at $5.00. View the best growth stocks for 2025 here. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $16.45 million for the quarter, compared to analysts' expectations of $18.76 million. Neuronetics had a negative net margin of 50.09% and a negative trailing twelve-month return on equity of 141.24%. When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' top institutional shareholders include Balyasny Asset Management L.P. (4.88%), Geode Capital Management LLC (1.03%), Renaissance Technologies LLC (0.52%) and Accurate Wealth Management LLC (0.26%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, Stephen Furlong, Robert Cascella, William Andrew Macan and Glenn P Muir. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), General Electric (GE), Intel (INTC), Bank of America (BAC) and Nokia Oyj (NOK). Company Calendar Last Earnings8/12/2024Today2/18/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees180Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside-6.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-50.09% Pretax Margin-50.09% Return on Equity-141.24% Return on Assets-32.77% Debt Debt-to-Equity Ratio4.90 Current Ratio3.16 Quick Ratio2.87 Sales & Book Value Annual Sales$71.35 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book4.24Miscellaneous Outstanding Shares30,350,000Free Float27,374,000Market Cap$151.75 million OptionableOptionable Beta2.17 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:STIM) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.